Serious adverse events "Defined as events that result in death, hospitalization, prolongation of hospitalization, or are life threatening (based on the judgment of the study physician)" (Quinn 2010) · Apathy in people with mild‐to‐moderate Alzheimer's disease
Omega‐3 PUFA supplements showed no clear difference in serious adverse events "Defined as events that result in death,… compared with placebo (high certainty).
1 finding from 1 review
QoL · Apathy in people with mild‐to‐moderate Alzheimer's disease
2 findings from 1 review
Depressive symptoms · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Mental health outcomes · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Cognitive function · Apathy in people with mild‐to‐moderate Alzheimer's disease
2 findings from 1 review
IADL · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Intervention not reported
Quality of life (Asthma Quality of Life Questionnaire, with 32 items, 0 to 7 points per item) · People with asthma (mostly mild or moderate)
1 finding from 1 review
Intervention not reported
Asthma symptoms (different severity scores; change from baseline) · People with asthma (mostly mild or moderate)
1 finding from 1 review
Intervention not reported
Asthma control (weekly number of attacks) · People with asthma (mostly mild or moderate)
1 finding from 1 review
Intervention not reported
Forced expiratory volume in one second (change from baseline FEV1 (L)) · People with asthma (mostly mild or moderate)
1 finding from 1 review
Intervention not reported
Reduced asthma medication usage · People with asthma (mostly mild or moderate)
The intervention may leads to higher reduced asthma medication usage (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events · People with asthma (mostly mild or moderate)
1 finding from 1 review
All‐cause mortality · general population including those at moderate to high risk of CVD, mean age between 30 and 75
Systematic screening showed no clear difference in all‐cause mortality compared with no/opportunistic screening (low certainty).
1 finding from 1 review
Stroke · general population including those at moderate to high risk of CVD, mean age between 30 and 75
Systematic screening showed no clear difference in stroke (total) compared with no/opportunistic screening (low certainty).
1 finding from 1 review
Total coronary heart disease · general population including those at moderate to high risk of CVD, mean age between 30 and 75
Systematic screening showed no clear difference in coronary heart disease (total) compared with no/opportunistic screening (low certainty).
1 finding from 1 review
Cholesterol mg/dL · general population including those at moderate to high risk of CVD, mean age between 30 and 75
1 finding from 1 review
Systolic blood pressure · general population including those at moderate to high risk of CVD, mean age between 30 and 75
1 finding from 1 review
Diastolic blood pressure · general population including those at moderate to high risk of CVD, mean age between 30 and 75
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Median (mean) time to use of rescue medication · adults with moderate or severe acute postoperative pain
1 finding from 1 review